Effect of acacia polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A randomized multicenter feeding trial

Ogawa,Sosuke; Matsumae,Tomoyuki; Kataoka,Takeshi; Yazaki,Yoshikazu; Yamaguchi,Hideyo

doi:10.3892/etm.2013.1029

Effect of acacia polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A randomized multicenter feeding trial

Authors:
- Sosuke Ogawa
- Tomoyuki Matsumae
- Takeshi Kataoka
- Yoshikazu Yazaki
- Hideyo Yamaguchi
View Affiliations

Affiliations: mimozax Co., Ltd., Hatsukaichi-shi, Hiroshima 738-0034, Japan, Department of Chemical Engineering, Monash University, Clayton, Victoria 3800, Australia, Research Center, Total Technological Consultant Co., Ltd., Shibuya-ku, Tokyo 150-0021, Japan
Published online on: March 26, 2013 https://doi.org/10.3892/etm.2013.1029
Pages: 1566-1572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous in vitro and animal studies, as well as clinical trials have indicated that plant-derived polyphenols exert beneficial effects on glucose intolerance or type 2 diabetes. This clinical study aimed to investigate the effects of acacia polyphenol (AP) on glucose and insulin responses to an oral glucose tolerance test (OGTT) in non‑diabetic subjects with impaired glucose tolerance (IGT). A randomized, double-blind, placebo-controlled trial was conducted in a total of 34 enrolled subjects. The subjects were randomly assigned to the AP-containing dietary supplement (AP supplement; in a daily dose of 250 mg as AP; n=17) or placebo (n=17) and the intervention was continued for 8 weeks. Prior to the start of the intervention (baseline) and after 4 and 8 weeks of intervention, plasma glucose and insulin were measured during a two-hour OGTT. Compared with the baseline, plasma glucose and insulin levels at 90 and/or 120 min, as well as the total area under the curve values during the OGTT (AUC0→2h) for glucose and insulin, were significantly reduced in the AP group, but not in the placebo group after intervention for 8 weeks. The decline from baseline in plasma glucose and insulin at 90 or 120 min of the OGTT for the AP group was significantly greater compared with that of the placebo group after 8 weeks of intervention. No AP supplement-related adverse side‑effects nor any abnormal changes in routine laboratory tests and anthropometric parameters were observed throughout the study period. The AP supplement may have the potential to improve glucose homeostasis in subjects with IGT.

View Figures

View References

1.	Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: estimates for the year 2000 and projection for 2030. Diabetes Care. 27:1047–1053. 2004.PubMed/NCBI
2.	Danaei G, Finucane MM, Lu Y, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 378:31–40. 2011.
3.	International Diabetes Federation: Diabetes Atlas. 3rd edition. International Diabetes Federation; Brussels, Belgium: 2006
4.	Chen JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoo KH and Hu FB: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 301:2129–2140. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Tuomilehto J, Lindström J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344:1343–1350. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Lindström J, Ilanne-Parikka P, Peltonen M, et al: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finish Diabetes Prevention Study. Lancet. 368:1673–1679. 2006.PubMed/NCBI
7.	Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H and Poutanen K: Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci. 11:1365–1402. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Aron PM and Kennedy JA: Flavan-3-ols: nature, occurrence and biological activity. Mol Nutr Food Res. 52:79–104. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Yazaki Y: Acacia storyi: a potential tannin-producing species. Australian Forestry. 60:24–28. 1997. View Article : Google Scholar
10.	Roux DG and Maihs EA: Condensed tannins. 3 Isolation and estimation of (−)-7:3′:4′:5′-tetrahydroxyflavan-3-ol, (+)-catechin and (+)-gallocatechin from black-wattle-bark extract. Biochem J. 74:44–49. 1960.
11.	Roux DG and Paulus E: Condensed tannins. 7 Isolation of (−)-7:3′:4′-trihydroxyflavan-3-ol [(−)-fisetinidol], a naturally occurring catechin from black-wattle heartwood. Biochem J. 78:120–123. 1961.
12.	Roux DG, Maihs EA and Paulus E: Condensed tannins. 9 Distribution of flavonoid compounds in the heartwood and barks of some interrelated wattles. Biochem J. 78:834–839. 1961.PubMed/NCBI
13.	Kusano R, Ogawa S, Matsuo Y, Tanaka T, Yazaki Y and Kouno I: α-Amylase and lipase inhibitory activity and structural characterization of acacia bark proanthocyanidins. J Nat Prod. 74:119–128. 2011.
14.	Drewes SE and Roux DG: Condensed tannins. 15 Interrelationships of flavonoid components in wattle-bark extract. Biochem J. 87:167–172. 1963.PubMed/NCBI
15.	Roux DG and Evelyn SR: Condensed tannins. 1 A study of complex leuco-anthocyanins present in condensed tannins. Biochem J. 69:530–538. 1958.PubMed/NCBI
16.	Zheng G, Lin Y and Yazaki Y: Comparing molecular size distribution of tannin extracts from Acacia mearnsii bark from different countries. Holzforschung. 42:407–408. 1988.
17.	Ikarashi N, Toda T, Okaniwa T, Ito K, Ochiai W and Sugiyama K: Anti-obesity and anti-diabetic effects of acacia polyphenol in obese diabetic KKAy mice fed high-fat diet. Evid Based Complement Alternat Med. 2011:9520312011. View Article : Google Scholar : PubMed/NCBI
18.	Ikarashi N, Takeda R, Ito K, Ochiai W and Sugiyama K: The inhibition of lipase and glucosidase activities by acacia polyphenol. Evid Based Complement Alternat Med. 2011:2720752011. View Article : Google Scholar : PubMed/NCBI
19.	Kataoka T, Ogawa S, Matsumae T, Yazaki Y and Yamaguchi H: Safety of acacia polyphenol dietary supplement: safety evaluation studies in healthy male adults. Pharmacometrics. 80:43–52. 2011.(In Japanese).
20.	Japan Diabetes Society: Guidelines for Treatment of Diabetes 2002–2003. Bunkodo, Tokyo: 2002, (In Japanese).
21.	American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 27(Suppl 1): S5–S10. 2004. View Article : Google Scholar
22.	Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G and Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 85:2402–2410. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Bonora E, Kiechl S, Willeit J, et al: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 47:1643–1649. 1998. View Article : Google Scholar : PubMed/NCBI
24.	Grassi D, Lippi C, Necozione S, Desideri G and Ferri C: Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr. 81:611–614. 2005.PubMed/NCBI
25.	Grassi D, Desideri G, Necozione S, et al: Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr. 138:1671–1676. 2008.
26.	The DECODE study group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 354:617–662. 1999. View Article : Google Scholar : PubMed/NCBI
27.	Osei K, Rhinesmith S, Gaillard T and Schuster D: Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in prediabetic African Americans: implications for primary diabetes prevention. Diabetes Care. 27:1439–1446. 2004. View Article : Google Scholar
28.	Thalhammer C, Balzuweit B, Busjahn A, Walter C, Luft FC and Haller H: Endothelial cell dysfunction and arterial wall hypertrophy are associated with disturbed carbohydrate metabolism in patients at high risk for cardiovascular disease. Arterioscler Thromb Vas Biol. 19:1173–1179. 1999. View Article : Google Scholar : PubMed/NCBI
29.	McNeeley MJ, Boyko EJ, Leonetti DL, Kahn SE and Fujimoto WY: Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care. 26:758–763. 2003. View Article : Google Scholar : PubMed/NCBI
30.	McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C and Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Am Intern Med. 139:802–809. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Kashiwabara H, Inaba M, Maruno Y, et al: Insulin levels during fasting and the glucose tolerance test and Homa’s index predict subsequent development of hypertension. J Hypertens. 18:83–88. 2000.